Compare Quest Diagnostics Inc (DGX) vs SoFi Technologies Inc (SOFI) Price & Performance

Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.

The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.

SoFi Technologies (SOFI) trades at $15.66, down 0.64% on the day and near its 52-week low, reflecting bearish technical signals. The company reported strong revenue growth to $3.61 billion in 2025 with a net income of $481.32 million, but negative operating cash flow and high leverage remain concerns. Analyst sentiment is mixed with a consensus price target of $21.58, implying significant upside, while recent news highlights growth in loan originations and stablecoin initiatives.

The outlook for SOFI hinges on sustaining profitability amid competitive pressures and interest rate sensitivity. Upside potential exists from execution on guidance and market share gains, but risks include persistent cash burn and macroeconomic headwinds. Investors should weigh the growth trajectory against valuation premiums and operational challenges.